Refractory rheumatoid arthritis. Therapeutic options

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) frequently presents as refractory disease due to its chronic and non-remitting nature.
• Aggravating comorbid conditions significantly impact RA management and patient outcomes.
• Current therapeutic strategies for refractory RA are limited, necessitating a review of available options.

Purpose of the Study:

• To review current pharmacologic treatment options for refractory rheumatoid arthritis.
• To discuss the potential risks and benefits associated with various treatment modalities.
• To provide clinicians with an evidence-based overview for managing complex RA cases.

Main Methods:

• Literature review of available pharmacologic treatments for refractory rheumatoid arthritis.
• Analysis of clinical data and published studies on treatment efficacy and safety.
• Synthesis of information on cyclosporin, high-dose methotrexate, combination therapies, and corticosteroid use.

Main Results:

• Refractory RA necessitates careful consideration of comorbid conditions.
• Pharmacologic options include cyclosporin, high-dose methotrexate, combination second-line agents, and strategic corticosteroid use.
• Each treatment option presents a unique profile of potential risks and benefits that must be evaluated.

Conclusions:

• Management of refractory rheumatoid arthritis demands a comprehensive approach, including addressing comorbidities.
• A range of pharmacologic agents, from conventional to advanced therapies, are available for refractory RA.
• Informed decision-making regarding treatment selection requires a thorough understanding of the risks and benefits of each option.